Gainers

• NovoCure (NASDAQ:NVCR) shares moved upwards by 27.7% to $19.88 during Thursday's regular session. The market value of their outstanding shares is at $1.8 billion. The company's, Q2 earnings came out today.
• Zhengye Biotechnology (NASDAQ:ZYBT) shares moved upwards by 21.01% to $1.67. The company's market cap stands at $65.4 million.
• Neuphoria Therapeutics (NASDAQ:NEUP) shares moved upwards by 20.6% to $4.02. The company's market cap stands at $17.9 million.
• Medpace Holdings (NASDAQ:MEDP) stock moved upwards by 15.02% to $607.46. The company's market cap stands at $15.0 billion. As per the news, the Q2 earnings report came out yesterday.
• Gelteq (NASDAQ:GELS) shares rose 13.56% to $0.77. The company's market cap stands at $7.2 million.
• Advanced Biomed (NASDAQ:ADVB) shares increased by 12.65% to $13.8. The market value of their outstanding shares is at $20.0 million.

Losers

• China SXT Pharmaceuticals (NASDAQ:SXTC) stock decreased by 82.9% to $0.34 during Thursday's regular session. The market value of their outstanding shares is at $77.2 million.
• Nuwellis (NASDAQ:NUWE) shares declined by 21.41% to $2.24.
• Jaguar Health (NASDAQ:JAGX) shares decreased by 21.06% to $1.05. The market value of their outstanding shares is at $6.5 million.
• Jupiter Neurosciences (NASDAQ:JUNS) shares declined by 15.81% to $0.15. The market value of their outstanding shares is at $8.4 million.
• Lakewood-Amedex (NASDAQ:LABT) stock declined by 15.25% to $2.89. The market value of their outstanding shares is at $5.9 million.
• Community Health System (NYSE:CYH) shares decreased by 14.28% to $2.76. The company's market cap stands at $453.7 million. As per the press release, Q2 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.